{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:47:37Z","timestamp":1776210457426,"version":"3.50.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex&apos;s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS121249"],"award-info":[{"award-number":["R01NS121249"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS122859"],"award-info":[{"award-number":["R01NS122859"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000985","name":"Assisi Foundation of Memphis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000985","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA281823"],"award-info":[{"award-number":["U01CA281823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xcrm.2026.102626","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:07:55Z","timestamp":1771344475000},"page":"102626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cell therapy for brain tumors: The first 60 years"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3730-9642","authenticated-orcid":false,"given":"Sanya","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-0644","authenticated-orcid":false,"given":"Giedre","family":"Krenciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102626_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/neuonc\/nov249","article-title":"Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010","volume":"18","author":"Rouse","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib2","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102626_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3171\/jns.1984.61.5.0809","article-title":"The first primary brain-tumor operation","volume":"61","author":"Kirkpatrick","year":"1984","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2026.102626_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","article-title":"Childhood brain tumors: current management, biological insights, and future directions","volume":"23","author":"Pollack","year":"2019","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.xcrm.2026.102626_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib7","first-page":"95","article-title":"Adverse health outcomes and health-related quality of life (HRQoL) among long-term adolescent and young adult (AYA) brain tumour survivors: results from the population-based SURVAYA study","volume":"33","author":"Angoumis","year":"2025","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib8","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/ajc.1933.873","article-title":"Absorption of the Protective Agent from Rats Resistant to a Transplantable Sarcoma","volume":"17","author":"Woglom","year":"1933","journal-title":"Am. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib10","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102626_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib12","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102626_bib14","first-page":"1269","article-title":"Cellular immunotherapy of cerebral glioblastoma. Apropos of 2 results]","volume":"50","author":"Trouillas","year":"1969","journal-title":"J. Med. Lyon"},{"key":"10.1016\/j.xcrm.2026.102626_bib17","first-page":"2101","article-title":"Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial","volume":"46","author":"Jacobs","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006293606710","article-title":"Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas","volume":"45","author":"Quattrocchi","year":"1999","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma","volume":"6","author":"Yaghoubi","year":"2009","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib25","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-0296","article-title":"Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma","volume":"74","author":"Schuessler","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib26","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib30","first-page":"109","article-title":"Adjuvant Immunotherapy for Malignant Brain Tumors","volume":"2","author":"TAKAKURA","year":"1972","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00195603","article-title":"Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor","volume":"4","author":"Kitahara","year":"1987","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib98","first-page":"1861","article-title":"Autologous natural killer cell therapy for human recurrent malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib123","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib134","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102626_bib139","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib140","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib142","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102626_bib44","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib29","first-page":"143","article-title":"[Active immunotherapy of cerebral tumor. 20 cases]","volume":"16","author":"Trouillas","year":"1970","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.xcrm.2026.102626_bib31","first-page":"141","article-title":"Adjuvant immunotherapy for malignant brain tumors in infants and children","volume":"1","author":"Takakura","year":"1975","journal-title":"Childs Brain"},{"key":"10.1016\/j.xcrm.2026.102626_bib32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(197709)40:3<1037::AID-CNCR2820400311>3.0.CO;2-9","article-title":"Immunotherapy with autologous white cell infusions (\u201clymphocytes\u201d) in the treatment of recurrrent glioblastoma multiforme: a preliminary report","volume":"40","author":"Young","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ana.410040404","article-title":"Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study","volume":"4","author":"Neuwelt","year":"1978","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2026.102626_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2176\/nmc.19.335","article-title":"Treatment of malignant glioma by immunotherapy using lymphocytes sensitized with tumor-specific immune RNA (author's transl)]","volume":"19","author":"Mita","year":"1979","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.xcrm.2026.102626_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2176\/nmc.21.179","article-title":"[Immunotherapy for malignant gliomas (author's transl)]","volume":"21","author":"Ishizawa","year":"1981","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.xcrm.2026.102626_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00177901","article-title":"Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study","volume":"2","author":"Steinbok","year":"1984","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01406665","article-title":"Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results","volume":"89","author":"Vaquero","year":"1987","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.xcrm.2026.102626_bib36","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/archsurg.1987.01400240131025","article-title":"Salvage immunotherapy of malignant glioma","volume":"122","author":"Ingram","year":"1987","journal-title":"Arch. Surg."},{"key":"10.1016\/j.xcrm.2026.102626_bib37","first-page":"489","article-title":"Preliminary clinical trial of immunotherapy for malignant glioma","volume":"6","author":"Ingram","year":"1987","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.xcrm.2026.102626_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/01616412.1990.11739955","article-title":"Immunotherapy for recurrent malignant glioma: an interim report on survival","volume":"12","author":"Ingram","year":"1990","journal-title":"Neurol. Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01407174","article-title":"Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma","volume":"98","author":"Vaquero","year":"1989","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.xcrm.2026.102626_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF01405696","article-title":"Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study","volume":"109","author":"Vaquero","year":"1991","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.xcrm.2026.102626_bib41","first-page":"107","article-title":"[Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application]","volume":"58","author":"Moriki","year":"1989","journal-title":"Nihon Geka Hokan"},{"key":"10.1016\/j.xcrm.2026.102626_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2176\/nmc.41.387","article-title":"Adoptive immunotherapy for malignant brain tumors using human peripheral blood mononuclear cells activated by the Streptococcal preparation OK-432","volume":"41","author":"Hirotsu","year":"2001","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.xcrm.2026.102626_bib45","first-page":"4420","article-title":"Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor","volume":"41","author":"Lotze","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","article-title":"Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes","volume":"155","author":"Grimm","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.6332379","article-title":"Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2","volume":"225","author":"Mul\u00e9","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102626_bib48","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3171\/jns.1986.64.5.0743","article-title":"Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report","volume":"64","author":"Jacobs","year":"1986","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2026.102626_bib18","first-page":"1078","article-title":"Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report","volume":"34","author":"Silvani","year":"1994","journal-title":"Neurosurgery"},{"key":"10.1016\/j.xcrm.2026.102626_bib19","first-page":"276","article-title":"Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor","volume":"6","author":"Itoh","year":"1988","journal-title":"Radiat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R","article-title":"Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma","volume":"76","author":"Hayes","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3171\/jns.1987.66.4.0519","article-title":"Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2","volume":"66","author":"Shimizu","year":"1987","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2026.102626_bib51","first-page":"1930","article-title":"Adoptive immunotherapy in patients with malignant glioma]","volume":"14","author":"Yoshida","year":"1987","journal-title":"Gan To Kagaku Ryoho."},{"key":"10.1016\/j.xcrm.2026.102626_bib52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/1097-0142(19880815)62:4<665::AID-CNCR2820620403>3.0.CO;2-O","article-title":"Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2","volume":"62","author":"Merchant","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib53","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1227\/00006123-198812000-00007","article-title":"Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor","volume":"23","author":"Merchant","year":"1988","journal-title":"Neurosurgery"},{"key":"10.1016\/j.xcrm.2026.102626_bib54","first-page":"119","article-title":"Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas]","volume":"40","author":"Yoshida","year":"1988","journal-title":"No Shinkei"},{"key":"10.1016\/j.xcrm.2026.102626_bib55","first-page":"5011","article-title":"Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors","volume":"48","author":"Yoshida","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1227\/00006123-198911000-00019","article-title":"Sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine-activated killer cells and recombinant interleukin-2: case reports","volume":"25","author":"Atkinson","year":"1989","journal-title":"Neurosurgery"},{"key":"10.1016\/j.xcrm.2026.102626_bib57","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3171\/jns.1989.70.2.0175","article-title":"Intratumoral LAK cell and interleukin-2 therapy of human gliomas","volume":"70","author":"Barba","year":"1989","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2026.102626_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01402326","article-title":"Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report","volume":"99","author":"Naganuma","year":"1989","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.xcrm.2026.102626_bib59","first-page":"991","article-title":"Adoptive immunotherapy in patients with medulloblastoma by LAK cells]","volume":"41","author":"Shimizu","year":"1989","journal-title":"No Shinkei"},{"key":"10.1016\/j.xcrm.2026.102626_bib60","first-page":"283","article-title":"Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme","volume":"34","author":"Munari","year":"1990","journal-title":"J. Neurosurg. Sci."},{"key":"10.1016\/j.xcrm.2026.102626_bib61","first-page":"1001","article-title":"[Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells]","volume":"18","author":"Nitta","year":"1990","journal-title":"Noshinkeigeka"},{"key":"10.1016\/j.xcrm.2026.102626_bib62","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0140-6736(90)90205-J","article-title":"Preliminary trial of specific targeting therapy against malignant glioma","volume":"335","author":"Nitta","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102626_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1227\/00006123-199101000-00003","article-title":"Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy","volume":"28","author":"Lillehei","year":"1991","journal-title":"Neurosurgery"},{"key":"10.1016\/j.xcrm.2026.102626_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2008-1071326","article-title":"Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma","volume":"23","author":"Thomas","year":"1992","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.xcrm.2026.102626_bib65","first-page":"331","article-title":"Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells","volume":"4","author":"Blancher","year":"1993","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.xcrm.2026.102626_bib66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2176\/nmc.33.448","article-title":"Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients","volume":"33","author":"Ibayashi","year":"1993","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.xcrm.2026.102626_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01053935","article-title":"Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA","volume":"15","author":"Jeffes","year":"1993","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib68","first-page":"547","article-title":"Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report","volume":"45","author":"Nagane","year":"1993","journal-title":"No To Shinkei"},{"key":"10.1016\/j.xcrm.2026.102626_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01533386","article-title":"Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients","volume":"39","author":"Boiardi","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2176\/nmc.35.22","article-title":"Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors","volume":"35","author":"Nakagawa","year":"1995","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.xcrm.2026.102626_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00177476","article-title":"Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors","volume":"27","author":"Sankhla","year":"1996","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02478872","article-title":"Long-term survival in a young patient with anaplastic glioma","volume":"14","author":"Naganuma","year":"1997","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.xcrm.2026.102626_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1040-8428(01)00122-6","article-title":"Adoptive cellular immunotherapy for the treatment of malignant gliomas","volume":"39","author":"Hayes","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2026.102626_bib74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(01)00120-2","article-title":"Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report","volume":"39","author":"Huang","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2026.102626_bib75","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00002371-200409000-00009","article-title":"Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma","volume":"27","author":"Dillman","year":"2004","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib76","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/CJI.0b013e3181b2910f","article-title":"Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma","volume":"32","author":"Dillman","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01406615","article-title":"An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK)","volume":"94","author":"Okamoto","year":"1988","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.xcrm.2026.102626_bib78","first-page":"24","article-title":"Epitope analysis of cluster 1 and NK cell-related monoclonal antibodies","volume":"14","author":"Hida","year":"1991","journal-title":"Br. J. Cancer Suppl."},{"key":"10.1016\/j.xcrm.2026.102626_bib94","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102626_bib81","first-page":"1065","article-title":"MR of recurrent high-grade astrocytomas after intralesional immunotherapy","volume":"17","author":"Smith","year":"1996","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"10.1016\/j.xcrm.2026.102626_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00177482","article-title":"Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III\/IV astrocytoma","volume":"27","author":"Holladay","year":"1996","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002620050405","article-title":"Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2","volume":"45","author":"Kruse","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3171\/jns.1998.89.1.0042","article-title":"Systemic T cell adoptive immunotherapy of malignant gliomas","volume":"89","author":"Plautz","year":"1998","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2026.102626_bib83","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1349-7006.1999.tb00781.x","article-title":"Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes","volume":"90","author":"Tsurushima","year":"1999","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib84","first-page":"2209","article-title":"T cell adoptive immunotherapy of newly diagnosed gliomas","volume":"6","author":"Plautz","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1006456421177","article-title":"A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III\/IV astrocytoma","volume":"48","author":"Wood","year":"2000","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib86","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3171\/foc.2000.9.6.10","article-title":"Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes","volume":"9","author":"Sloan","year":"2000","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.xcrm.2026.102626_bib87","first-page":"3294","article-title":"Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas","volume":"9","author":"Tsuboi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib88","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0028-1093333","article-title":"High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors","volume":"39","author":"Peres","year":"2008","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.xcrm.2026.102626_bib89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000313629","article-title":"Therapeutic Efficacy of Adoptive Cell Transfer on Survival of Patients with Glioblastoma Multiforme: Case Reports","volume":"3","author":"Katakura","year":"2010","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib90","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/icb.2012.19","article-title":"Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme","volume":"90","author":"Crough","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102626_bib91","first-page":"3921","article-title":"Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated \u03b1\u03b2 T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma","volume":"37","author":"Kanemura","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib92","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102626_bib93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41467-018-03217-9","article-title":"Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells","volume":"9","author":"Kirkin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102626_bib95","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0167-5699(91)90068-5","article-title":"Modulation of T-cell function by gliomas","volume":"12","author":"Roszman","year":"1991","journal-title":"Immunol. Today"},{"key":"10.1016\/j.xcrm.2026.102626_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/248701a0","article-title":"Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system","volume":"248","author":"Zinkernagel","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102626_bib97","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1158\/1078-0432.CCR-04-2588","article-title":"Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors","volume":"11","author":"Facoetti","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib99","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","article-title":"Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma","volume":"22","author":"Khatua","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib100","article-title":"Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I\/IIa trial","volume":"16","author":"Lim","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102626_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110345","article-title":"Intra-lesion injection of activated Natural Killer (NK) cells in recurrent malignant brain tumors","volume":"120","author":"Asl","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2026.102626_bib102","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib103","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/s12885-025-14314-6","article-title":"The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory\/recurrent brain tumors","volume":"25","author":"Mahdizadeh","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib104","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102626_bib105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102626_bib106","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/eji.1830230705","article-title":"New simplified molecular design for functional T cell receptor","volume":"23","author":"Brocker","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102626_bib107","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41586-023-06706-0","article-title":"Targeting of intracellular oncoproteins with peptide-centric CARs","volume":"623","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102626_bib108","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102626_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib109","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib111","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-24-1465","article-title":"Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors","volume":"15","author":"Timpanaro","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102626_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.815726","article-title":"The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues","volume":"12","author":"Burns","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.718030","article-title":"T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges","volume":"11","author":"Haydar","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib114","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10555-024-10208-4","article-title":"CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials","volume":"43","author":"Ronsley","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.xcrm.2026.102626_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1596499","article-title":"CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence","volume":"16","author":"Yaacoub","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102626_bib117","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102626_bib118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","article-title":"Advances in CAR-T therapy for central nervous system tumors","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.102626_bib119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41571-025-01102-1","article-title":"The development of CAR T cells for patients with CNS malignancies","volume":"23","author":"Binder","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-024-04909-7","article-title":"Clinical progress in the development of CAR T cells to treat malignant glioma","volume":"171","author":"Grewal","year":"2025","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib121","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00262-025-04222-w","article-title":"CAR-T cells immunotherapy in the treatment of glioblastoma","volume":"74","author":"Kr\u00f3likowska","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib122","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11060-024-04876-z","article-title":"CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws","volume":"171","author":"Sabahi","year":"2025","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102626_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib125","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102626_bib127","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102626_bib128","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/neuonc\/noaf064","article-title":"Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial","volume":"27","author":"Gust","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib129","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.669071","article-title":"Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma","volume":"11","author":"Durgin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib131","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.xcrm.2026.102626_bib132","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib133","article-title":"First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib135","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102626_bib136","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib137","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib138","article-title":"Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety","volume":"6","author":"Barish","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib141","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102626_bib144","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102626_bib145","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib146","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas","volume":"9","author":"Brandsma","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib147","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib148","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102626_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009504","article-title":"Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy","volume":"18","author":"Brummer","year":"2022","journal-title":"PLoS Comput. Biol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:52:04Z","timestamp":1776207124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666379126000431"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102626","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell therapy for brain tumors: The first 60 years","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102626"}}